| Global Research Trends

Wednesday, 24 February 2021

Epigenetics Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Epigenetics Market - Regional Analysis

On the basis of geography, global Epigenetics Market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America epigenetics market is expected to hold dominant position in the global market, owing to increasing funding for research and development activities by government. Furthermore, Asia Pacific epigenetics market is expected to be fastest growing region owing to high incidence of cancer. For instance, according to article in Japanese Journal of Clinical Oncology in 2012, more than 70% of total cancer mortality is reported in Asia Pacific region and it is projected to rise continuously to 16 million by 2025.

Epigenetics is the structural changes in chromosomal regions, which signal or perpetuate alteration in gene expression by turning it on or off. Epigenetic alteration includes DNA methylation, histone modification, chromatin remodeling, genomic imprinting, X chromosome inactivation, and non-coding RNA regulation affecting gene transcription. Epigenetics is applied for the studies of oncology, developmental biology, drug development, and non-oncological disorders such as Alzheimer’s disease and respiratory disease. Epigenetics has applications in in forensic science for paternity testing, distinguishing between identical twins, identification of tissue origin, and for estimation of postmortem interval. Increasing application of epigenetics is expected to propel growth of the epigenetics market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1772

Epigenetics Market Drivers

Increasing research to study the epigenetics of the genome (study called epigenomics) is expected to boost growth of the epigenetics market over the forecast period. Genome-wide epigenetic studies play an important role in the diagnostics of human diseases. Moreover, implementation of epigenetics for oncology research is estimated to propel the growth of epigenetics market. For instance, Constellation Pharmaceuticals, in April 2018, invested US$ 100 million for development of cancer epigenetics platform and ongoing ProSTAR and ORIOn-E trials, which are designed to demonstrate the potential for CPI-1205 and CPI-0610, used for cancer therapy. Moreover, increasing whole genome sequencing projects such as Human Genome Project is resulting into increasing adoption of epigenetic-based products, which in turn is driving growth of the epigenetics market size.

Increasing government initiatives to enhance epigenetic research is fueling growth of the epigenetics market. For instance, in 2017, National Institutes of Health (NIH) planned to award 10 grants for supporting social epigenomics research in health disparities. The National Institute on Minority Health and Health Disparities (NIMHD), a part of the National Institutes of Health, committed US$ 26.2 million for nine awards over the term of five year. Moreover, in 2011, epigenetic related research was awarded US$ 11 million grant by the U.S. National Institute of Environmental Health Sciences. In same year, European Commission launched US$ 52.1 million project named BLUEPRINT, which aims to generate 100 reference epigenomes of healthy and leukaemic cells.

Furthermore, organic and inorganic growth strategies such as merger, collaboration, acquisition and product launches by market players of epigenetics market are expected to fuel growth of the epigenetics market. For instance, in 2012, Epizyme partnered with Summit, a subsidiary of Celgene to develop personalized therapeutics for patients with genetically defined cancers by inhibiting histone methyl transferases (HMTs), an important epigenetic target class. Under this agreement, Celgene will receive an exclusive license outside the U.S. to some of Epizyme’s programs for the period of three years and has the right to extend this option period for one year with additional funding. Moreover, In January 2016, Merck collaborated with the Cancer Research Technology in U.K., to develop inhibitors of protein arginine methyltransferase 5 (PRMT5).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/epigenetics-market-1772

Increasing incidence of cancer is also expected to upsurge epigenetics market in the near future. For instance, the global cancer prevalence was predicted to be 32.5 million in 2012, by Cancer Research UK, which is expected to increase by 68% by 2030. Furthermore, according to National Cancer Institute (NCI), people undiagnosed cancer patients reached nearly 14.5 million in 2014, and the number is expected to reach 19 million by 2024. Moreover, increasing prevalence of chronic disease is expected to boost growth of the epigenetics market. For instance, according to Center of Disease Control and Prevention (CDC), 2012, about half of the adult in U.S, which is 117 million, suffers from one or more chronic health conditions such as heart disease, stroke, cancer, type 2 diabetes, obesity, and arthritis

Epigenetics Market Restraint

High maintenance and cost of the instruments such as next generation sequencing or qPCR, implemented for epigenetic study are expected to be the key factors hindering growth of the epigenetics market.

Epigenetics Market – Competitor

Epigenetics market is highly fragmented. Major players operating in market include Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1772

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Cosmetic Dentistry Market Size Share Trends Forecast 2026

Cosmetic Dentistry Market Drivers:

The Cosmetic Dentistry Market is expected to witness significant growth over the forecast period, due to launch of innovative products in the market and advancements in technology of minimally invasive devices that are used in the cosmetic dentistry. For instance, in May 2018, Victoria House Foundation Inc. (VHF) launched R5, a state-of-the-art 5-axis grinding and milling machine. It is a highly automated machine with a tenfold blank changer for both dry and wet machining. In March 2018, Vericore LLC launched ZR Pro Zirconia, which is ideal for both anterior and posterior segments of the mouth. It has flexural strength, white and shaded discs, and esthetics in several thickness and is used to produce natural looking restorations from single to multiple-unit posterior bridges with satisfying results. In February 2018, 3D systems, a Canada-based company, launched Next Dent 5100 and 18 new Next Dent resins, which added 30 materials to Next Dent portfolio. It includes solutions for clinics and dental laboratories of all sizes ranging from small clinics to huge hospitals. This device facilitates high speed 3D printing of dental fixtures and devices.

Other factors that are expected to boost growth of the cosmetic dentistry market include, increasing awareness about cosmetic dentistry, high demand for dental implants and orthodontic appliances, and increasing medical tourism. According to a survey conducted by the American Academy of Cosmetic Dentistry in 2015, around 84% of the population go for whitening, bonding, and veneers.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1759

Cosmetic dentistry refers to any dental work that improves the appearance of gums or teeth. It focuses on improving dental aesthetics in size, shape, color, position, and alignment. It involves the addition of dental materials such as porcelain veneers, gum grafts, crowns, and bonding to gums or teeth, and removal of teeth structure and gums through procedures such as enameloplasty, gingivectomy, teeth whitening, gum depigmentation, laser whitening, and teeth straightening. Laser whitening is more effective as compared to other procedures for teeth whitening. Bonding in cosmetic dentistry involves the adhesion of a dentistry material onto both surfaces of the tooth, which is then sculpted, hardened, and polished. Dental bridges are used to replace one or more missing teeth. Bridge, which is made up of abutments, can consist of over three teeth in total and the average life of bridges is 10 years. Veneers are custom-made ultra-thin porcelain laminates that are bond directly to the teeth. They are used for enhancing the shape, closing gaps, and changing color of teeth. Dental implants are replacement for missing teeth and consist of three parts: implant devices made up of titanium, abutment, and a dental crown that is connected to the implant through the abutment. Gum lift raises and sculpts the gum line and reshapes the tissue and the underlying bones to improve the appearance of the teeth.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/cosmetic-dentistry-market-1759

Cosmetic Dentistry Market Regional Analysis:

North America is expected to hold dominant position in the market over the forecast period, owing to launch of novel products in the region. For instance, in 2015, a U.S.-based company, Whip Mix launched 3shape dental system, which provides technicians with automation and increased productivity. Europe is expected to witness significant growth in the cosmetic dentistry market, due to advancements in technology. For instance, in 2017, Digital Smile Design (DSD) Clinic launched a new technology, which uses aesthetic system with veneers and crowns. Asia Pacific is expected to witness significant growth over the forecast period, due to increasing number of dental patients and favorable government policies. According to a survey conducted by the Indian Dental Association in 2016, there will be a reduction of 7.5% to 5% on custom duties of surgical, medical, and dental equipment.

Cosmetic Dentistry Market Key Players:

Key players operating in the cosmetic dentistry market include, Danaher Corporation, Align Technology, Dentsply Sirona, 3M, Zimmer Biomet, Biocon, Shofu Dental Corporation, Thommen Medical, and Den Tech.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1759

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Endocrine Testing Market To Surpass US$ 4,878.1 Million By 2027 - Coherent Market Insights

Global Endocrine Testing Market, By Test (Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Human Chorionic Gonadotropin, Prolactin, Cortisol DHEA-S, Others) By Diagnostic Technology ( Immunoassay, Tandem Mass Spectrometry, Monoclonal and Polyclonal antibodies, Sensors Technologies, Clinical Chemistry , Others), By End User (Hospitals and Diagnostic Laboratories, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 3,403.0 million in 2020 and is expected to exhibit a CAGR of 5.3 % over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Key companies are focusing on product developments for testing of diabetes mellitus, one of the most common endocrinal disorders, globally. For instance, in 2018, Roche Diabetes Care India, a leading company in monitoring diabetes with their testing kits, launched a novel self- monitoring glucometer Accu-Chek Instant S for testing of glucose levels in blood of diabetic patients.

Moreover, companies are highly focused on innovation and advancements in rapid testing and diagnosis of diabetes to strengthen their market share in the global endocrine testing market. For instance, in 2019, iQ Group Global launched an innovative technology in saliva based glucose testing for diagnosis and testing the glucose level in blood.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1755

Global Endocrine Testing Market – Impact of Coronavirus (Covid-19) Pandemic

Due to the lockdown, diabetic patients are unable to visit diagnostic laboratories due to risk of diabetic patients getting infected by COVID-19 infections. Therefore, safety procedures such as maintaining social distancing, proper management of blood spills while collecting blood samples, and use of personal protection equipment must be followed and evaluated for patients having diabetic conditions, as diabetic patients are more prone towards the risk of COVID-19 infection..

According to Journal of Reproductive Science report in 2020, fundamental principles such as social distancing and use of personal protection equipment should be followed by clinicians of diagnostics laboratories while performing testing procedures on patients

According to Indian Society of Assisted Reproduction report in 2020, while conducting semen analysis, it should be ensured that the male candidate is COVID-19 negative by reverse transcription polymerase chain reaction (RT-PCR)

Browse 45 Market Data Tables and 35 Figures spread through 200 pages and in-depth TOC on “Global Endocrine Testing Market, By Test ( Thyroid, Insulin, Follicle Stimulating Hormone, Luteinizing, Hormone, Estradiol, Testosterone, Human Chorionic Gonadotropin, Prolactin, Cortisol DHEA-S, Others) By Diagnostic Technology ( Immunoassay, Tandem Mass Spectrometry, Monoclonal and Polyclonal antibodies, Sensors Technologies, Clinical Chemistry , Others), By End User (Hospitals and Diagnostic Laboratories, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/endocrine-testing-market-1755

The market is expected to gain significant growth during the forecast period, as various companies are focusing on research and development in the field of endocrine testing.

For instance, in 2018, MiraCare launched TechCrunch Disrupt SF, a novel self-monitoring fertility testing device for women who are suffering from fertility problems. TechCrunch Disrupt SF is a personalized self-monitoring device used for cycle predication in women by monitoring fertility hormone through urine samples in females.

Key Takeaways of the Global Endocrine Testing Market:

The global endocrine testing market is expected to exhibit a CAGR of 5.3 % over the forecast period, owing to robust product pipeline, and increasing approval of new endocrine testing devices and diagnostic procedures

Among test , insulin and thyroid segments are estimated to hold dominant position in the endocrine testing market in 2020, owing to rising prevalence of diabetes and thyroid related disorders (hypothyroidism and hyperthyroidism)

Among diagnosis technology type, sensor technologies endocrine testing market segment is estimated to hold dominant position in the endocrine testing market in 2020, due to rise technological advancements and increasing prevalence of endocrine related disorders

Among end user, diagnostic laboratories market segment is estimated to hold dominant position in the endocrine testing market in 2020, owing to rising diagnostic procedures due to high number of individuals suffering from fertility, diabetes, and thyroid related conditions

Key players operating in global endocrine testing market include Abbott Laboratories, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Beckmann Coulter, Inc., Agilent Technologies, Inc, Siemens Healthineers AG, BioMérieux SA, Quest Diagnostics, and F. Hoffmann-La Roche AG.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1755

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Betaxolol Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Betaxolol Market - Regional Analysis

Geographically, global Betaxolol Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the maximum share for ocular surgery, owing to high prevalence of diabetes and eye related disorders among the populace in the region. According to National Federation of the blind, 2014, around 1.3 million people were legally blind in the U.S. and estimated that over 75,000 people in the U.S. are expected to suffer from blindness or visual impairment annually. Furthermore, Asia Pacific betaxolol market is expected to witness significant growth owing to the presence of generic key players such as Lupin Ltd. And Cipla Ltd. especially in India, which are engaged in manufacturing the generics of betaxolol to retain the market share in the region.

Betaxolol is a racemic mixture and beta-adrenergic receptor inhibitor used to treat patients with chronic open-angle glaucoma or ocular hypertension. It was first approved by the U.S. Food and Drug Administration (FDA) in 1989, as an oral tablet. Betaxolol is used either alone or in combination with other medicines to lower down the pressure within the heart or eye. In the heart, Betaxolol decreases the cardiac contractility and rate selectively by actively binding and blocking beta-1 adrenergic receptors. This leads to reduction in cardiac output and lowers blood pressure. Topical applications in the eye reduces aqueous humor secretion and lowers the Intraocular Pressure (IOP) resulting in low risk of optic nerve damage and loss of vision in patients. Betaxolol further inhibits the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels. However, lightheadedness, drowsiness, dizziness, and headache are some of the symptoms reported while taking this medication at initial stage. For oral administration, Betaxolol is available as 10-mg and 20-mg tablets whereas in liquid form, it comes in 2.5, 5, 10, and 15 mL of bottles of 0.25% sterile ophthalmic suspension and prescribed as one to two drops in the affected eye twice daily.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1781

Betaxolol Market Drivers

Increasing prevalence of glaucoma worldwide is propelling growth of the market. According to the Glaucoma research Foundation, glaucoma is the leading cause of irreversible blindness worldwide. Around 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be suffering from glaucoma worldwide, in 2013. Furthermore, according to the American Academy of Ophthalmology, the prevalence of glaucoma is high in Africa and Latin America. Patients who fail to respond to medications, undergo trabeculectomy surgery. However, few patients do not get complete relief from glaucoma even after trabeculectomy surgery. Therefore, novel treatment options are required for providing relief to such patients. Reducing intra-ocular pressure is the most important long term medical need of refractory glaucoma patients, which can be overcome by the use of Betaxolol drug, this in turn is expected to create lucrative opportunities for market growth. Moreover, people suffering from diabetic retinopathy are more prone to glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Thus, increase diabetic patient pool may also augment the growth of the betaxolol market size.

Increasing prevalence of hypertension diseases is also expected to drive growth of the market at significant rate. According to the reports from a variety of sources, including Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) in 2015, the global prevalence of pulmonary arterial hypertension is projected to be 100,000 – 200,000, that is about 15 - 50 patients per million of the population. Although treatment available for pulmonary arterial hypertension is limited, beta-adrenergic receptor inhibitor, Prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors are available to decrease symptoms, slow down disease progression, and improve the quality of life.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/betaxolol-market-1781

Betaxolol Market Restraint

Stringent regulatory approvals to ensure the safety of drugs and patent expiry of betaxolol drugs such as Betoptic S and Betoptic Liq, are major challenge for growth of the market, as the generic versions of these drugs are sold at 70% to 80% lower prices as compared to the branded drugs.

Betaxolol Market – Competitive Landscape

Organic and inorganic strategies by market players such as merger, collaboration, acquisition, and research and development for expansion of their business across the regions is expected to boost growth of the market. For instance, in 2016, Humanwell Healthcare Group and PuraCap Pharmaceutical acquired Epic Pharma LLC for $550 million to expand both their commercial and manufacturing capabilities, as well as their presence in the U.S. and international generics market.

The market players operating in betaxolol market include Novartis AG, Genix Pharma (Pvt.) Ltd., East West Pharma, Hetero Healthcare Ltd. (GenX), Cadila Pharmaceuticals Ltd., Jawa Pharmaceuticals (INDIA) Pvt. Ltd., DAL Medical Services Company Ltd, Sentiss Pharma Pvt. Ltd., Humanwell Healthcare Group, and PuraCap Pharmaceutical LLC.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1781

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Nerve Repair and Regeneration Market Opportunity Analysis-2027

Nerve Repair and Regeneration Market Dynamics:-

Major growth factor for Nerve Repair and Regeneration Market is the growing prevalence of neurological disorders. According to a survey conducted by National Health Interview survey (NHIS) in 2014, and estimated 1.4 million people suffer from nerve injuries and around 900,000 people undergo surgeries for neurological disorders. Moreover, new drugs for nerve repair and regeneration in the pipeline are expected to boost growth of the nerve repair and regeneration market over the forecast period. For instance, Axogen Inc. a U.S.-based company received an approval from Food and Drug Administration (FDA) in 2015 to proceed with RECON STUDY to support an investigational new drug application. RECON study is a prospective, multicenter, randomized study to evaluate surgical repairs outputs of peripheral nerve disorders. It is currently in phase 3 clinical trial. Furthermore, mergers and acquisitions by key market players are expected to fuel growth of the market. For instance, AxoGen a U.S.-based company, which is a leading company in nerve regeneration partnered with LifeNet Health, a leading allograft bio-implant company for the processing of advanced nerve grafts. This partnership is expected to improve the access for treatment of patients suffering from peripheral nerve disorder, which in turn is expected to fuel growth in global nerve repair and regeneration market.

However, stringent rules and regulation for approval of new drugs and high cost of nerve repair and regeneration devices and surgeries are key factors restraining growth of the nerve repair and regeneration market size.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1762

The delicate and complex structures that make up the nervous system consists of spinal cord, brain and peripheral nerves. They are prone to various types of disorders such Alzheimer’s disease, Amyotrophic lateral sclerosis, Parkinson’s disease, multiple system atrophy, and multiple sclerosis. Nerve repair and regeneration refers to repair and regrowth of nervous cells or tissues. It usually includes various mechanisms like generation of new glia, neurons, axons, myelin and synapses. Nerve Regeneration is segmented between the Peripheral Nervous System (PNS) and Central nervous system (CNS). CNS consists of the brain and spinal cord and PNS consists of spinal and cranial nerves along with their associated ganglia. PNS has an intrinsic ability of regeneration whereas CNS is not capable of repair and regeneration. Clinical treatments of nerve repair and generation include surgery, nerve grafting, allografts, and xenografts. Surgery includes of different types such as stem cell therapy, nerve grafting, and direct neuropathy. Stem cell therapy uses stem cells to treat disorders such as neuromuscular and degenerative disorders. Nerve grafting is a surgical technique, which includes repairing injured portion of the nerve by using a segment of unrelated nerve as a bridge to join the injured nerve.

Nerve Repair and Regeneration Market Regional Analysis:-

North America nerve repair and regeneration market is expected to hold dominant position and is expected to witness significant growth over the forecast period, owing to adoption of inorganic growth model by key players for geographic expansion. For instance, in January 2018, NeuroMetrix and GlaxoSmithKline Plc. (GSK) consumer health care merged to increase and develop new Quell Wearable pain release technology, this is a non-invasive device used to treat and manage chronic pain associated by nerve repair surgeries.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/nerve-repair-and-regeneration-market-1762

GSK Consumer healthcare acquired ownership of Quell Technology for markets outside U.S. In 2018 Collagen Matrix a U.S. based company launched OssiMend Spine and Dura Matrix Dural Repair products, OssiMend is a bone graft matrix which is used to provide scaffold to a patient to help them grow a new bone. Dura Matrix provides scaffold to brain and spinal cord. Europe nerve repair and regeneration market is expected to grow at significant rate, owing to increasing prevalence of neurological disorders. According to a study conducted by National Institute of health (NIH), in 2017, Alzheimer’s disease is reported to be the most common type of dementia. Increasing number of geriatric population is in turn increasing number of patients suffering from Alzheimer disorder, around 16.51 million people are diagnosed with Alzheimer in Europe between 2014 and 2016.

Nerve Repair and Regeneration Market Key Players:-

Key players operating in nerve repair and regeneration market include AxoGen, Boston Scientific, Liva Nova, Integra Life Sciences, Medtronic, Abbott Laboratories, Stryker, Nevro, Polyganics, Neuvectra, OrthoMed S.A.S, St. Jude Medical, Cyberonics Inc., and others.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1762

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Tuesday, 23 February 2021

Diclofenac Patches Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Diclofenac Patches Market Drivers

Diclofenac patches market is expected to witness significant growth over the forecast period, owing to high prevalence of chronic pain disease. According to the American Academy of Pain Medicine (AAPM), in 2011, around 1.8 billion people suffered from chronic pain. Moreover, the National Institutes of Health (NIH) estimates that one in 10 people in the U.S. suffer from chronic pain. According to a study published in the British Medical Journal in 2016, nearly one-third to half of the population in the U.K. suffers from chronic pain. Moreover, according to the NIH estimates published in 2015 by the American Pain Society (APS), around 50 million people in the U.S. suffered from chronic pain. Moreover, rising prevalence of pain and increasing prevalence of diseases such as cancer and others are driving the diclofenac patches market growth. For instance, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S. and 609,640 people are expected to die from the disease. Furthermore, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. Moreover, India, China and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. In addition, according to the same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer deaths, in less developed regions.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1792

Diclofenac is nonsteroidal anti-inflammatory drug (NSAID), which works in reducing hormones that cause inflammation and pain in the body. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic class of analgesic compounds, indicated to use in relieving post extraction pain. Diclofenac sodium is a commonly prescribed NSAID, which exhibits anti-inflammatory, analgesic and anti-pyretic activity. Diclofenac transdermal patches are used to get temporary relief of minor aches and pains of the muscle and joints that are applied directly to the area of pain. Transdermal diclofenac patches are found to be more effective as compared to the diclofenac tablets, owing to its once-daily application and lesser frequency of systemic adverse effects. Transdermal patches have been developed to offer innovative drug delivery system for diclofenac, with reduced incidence of systemic adverse effects due to lower plasma concentrations. Diclofenac patches are designed to treat pain associated with conditions such as gout, migraine, rheumatoid arthritis, sprains of muscles and joints and in mild to moderate fever in some cases.

Growing research developments in the NSAIDs to increase its effectiveness pain management and to extend its application in various areas of medical field, will drive the diclofenac patches market. For instance, a study published in the International Journal of Ophthalmology: April 2018, stated that, application of prophylactic non-steroidal anti-inflammatory drugs (NSAIDs) in pre- and post-cataract surgery may help to reduce the severity and frequency of the development of cystoid macular edema (CME) in the eyes of diabetic patients. Furthermore, in November 2017, researchers at the Indian Institute of Technology (IIT) Hyderabad have developed a novel skin patch which releases diclofenac at the target site in a controlled way in such way that, there will be constant release of the drug for as long as 12 hours. In addition, the drug has low half-life of one–two hours and therefor constant release for up to 12 hours offers consistent efficiency of diclofenac for a longer period.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/diclofenac-patches-market-1792

Diclofenac Patches Market Restraint

Diclofenac patches shows increased risk of heart attack or stroke when applied for longer duration than it prescribed, hindering the growth of diclofenac patches market size. NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Diclofenac patches also associated with major to minor side effects including abnormal pain, constipation, nausea and vomiting, skin rash and tinnitus.

Furthermore, an acceptance of diclofenac patch in the routine practice are low, compared to the diclofenac tablet or injection, which is probably due to the lack of awareness and a mental inertia to accept a new concept among the medical professionals and patients.

Diclofenac Patches Market - Regional Analysis

On the basis of region, global diclofenac patches market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in diclofenac patches market, owing to the higher prevalence of strains, sprains of muscle and joints, in this region. According to the National Health Statistics Reports: November 2016, there were an estimated 4,262 numbers of sprains and strains injury are reported in the U.S. between 2011 and 2014, which is also the major cause (41.4%) of natural injury in sports and recreation-related injury episodes.

Diclofenac Patches Market – Competitive Landscape

Key players operating in the diclofenac patches market include Pfizer Inc., Cadila Healthcare, GlaxoSmithKline Pharmaceuticals Ltd., Hisamitsu Pharmaceutical co. Inc. and Teikoku Seiyaku Co., Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1792

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Artificial Insemination Market Size Share Trends Forecast 2026

Artificial Insemination Market – Regional Insights

On the basis of the region, the global Artificial Insemination Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America market holds the dominant position in the global artificial insemination market, owing to technological advancements and favorable rules and regulations in the region. For instance, according to 2018 National Conference of State Legislature report, 14 states have laws mandating that employers offer insurance for fertility treatment. Hawaii, Arkansas, Texas, and Maryland mandate coverage for in vitro fertilization only, excluding inseminations.

Furthermore, Asia Pacific artificial insemination market is projected to witness significant growth owing to increasing prevalence of infertility among the populace and less stringent regulations. For instance, according to the United Nation Department of Economic and Social Affairs 2015 report shows a fertility rate decline from 1.3 to 1.4 children per woman.

Artificial insemination is a medical process for the purpose of achieving pregnancy through intentional introduction of sperm in a female’s uterus by means other than sexual intercourse. Artificial insemination is a fertility treatment process for humans, and is a usual practice for animal breeding. Recipients of artificial insemination include single mothers and infertile couples. Intrauterine Insemination (IUI) is the most widely operated method of artificial insemination. Increase prevalence of infertility is a key factor contributing to growth of artificial insemination market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1793

For instance, according to research published in 2012 PLOS Medicine, around 48.5 million couples worldwide were unable to conceive a child in 2010. Market players often offer home-use kits, including ovulation kits, pregnancy detection kits, and insemination devices.

Artificial Insemination Market Dynamics

Major pharmaceutical companies are vigorously developing products that are in clinical and preclinical trials and launching new insemination kits that have demonstrated potential benefits, which in turn is propelling the artificial insemination market growth. For instance, 2015 clinical trial study of Stork OTC kit showed effectiveness at delivering higher concentration of sperm to the cervix than natural intercourse. The Stork OTC delivered 3.23x higher value of sperm concentration to around 85% of the subjects in the study, whereas the remaining 15% showed no change in sperm concentration at the cervix. The Stork OTC received FDA over-the-counter approval in July 2014. The kit helps collect, insert, and transport sperms directly at the opening of the cervix for prolong duration, providing sperms the opportunity to enter into the uterus. The Stork OTC provides a safe and simple way for users to avoid unfavorable vaginal environment, to deliver the sperm.

Moreover, according to the National Women’s Health Resource Center, infertility impacts over 20 million women. According to 2017 United Nations World Population prospects report, total fertility is expected to decrease from 2.43 to 2.39 (children per woman) between 2020 and 2030. Increasing incidence of infertility among the global populace is majorly boosting growth of the artificial insemination market.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/artificial-insemination-market-1793

However, stringent regulations being implemented by most countries regarding who is applicable to receive fertility treatments, is hindering growth of the artificial insemination market size. For instance, Italy and France forbid lesbian couples and single women from using artificial insemination. Italy and Austria are among those banning all sperm and egg donations for IVF. Norway and Germany ban egg donations, however, allow sperm donations.

Artificial Insemination Market – Competitive Landscape

Key players operating in the global artificial insemination market include Pride Angel, Irvine Scientific, Hi-Tech Solutions, Rinovum Women’s Health, LLC, TenderNeeds Fertility, Conceivex, Inc., Labotech GmbH, Hamilton Throne Ltd., Biogenics Inc., Nikon Instruments Inc., Zander scientific Inc., and Surelife Pte Ltd. Key players are adoption growth strategies such as collaborations, acquisition, and new product launches to maintain a dominant position in the market. For instance, in 2016, Worthington Industries, in collaboration with Intellectual Ventures, launched the innovative AIS 3 and AIS 1.5 artificial insemination shield refrigerators equipped with the advanced artificial insemination shield canisters for holding samples.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1793

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Naloxone Market To Surpass US$ 884.8 Mn Threshold By 2026 - Coherent Market Insights

Global Naloxone Market, by Strength (0.4 mg/ml, 1mg/ml, 0.4mg/0.4ml, and 4mg/0.1ml and Others), by Route of Administration (Intranasal, Intramuscular/Subcutaneous, and Intravenous), by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 310.2 Mn in 2017, and is projected to exhibit a CAGR of 11.4% over the forecast period (2018 – 2026).

Increasing launches of new naloxone products in market is expected to be one of the major drivers fueling the global naloxone market growth in the near future. For instance, in November 2015, Adapt Pharma Inc. received the U.S. Food and Drug Administration’s (FDA’s) approval for its Narcan (naloxone HCl) nasal spray 4mg, indicated for emergency treatment of known or suspected opioid overdose. In June 2016, Sandoz Canada, a division of Novartis AG, launched S.O.S. naloxone hydrochloride injection in Canada. In July 2017, Indivior Inc., a subsidiary of Indivior Plc., received marketing authorization (MA) from the French Regulatory Agency, French National Agency for Medicines and Health Products Safety (ANSM), for Nalscue naloxone hydrochloride nasal spray, indicated for emergency treatment of characterized or suspected opioid overdose, in France.

Browse 47 Market Data Tables and 33 Figures spread through 199 Pages and in-depth TOC on Naloxone Market, by Strength (0.4 mg/ml, 1mg/ml, 0.4mg/0.4ml, and 4mg/0.1ml and Others), by Route of Administration (Intranasal, Intramuscular/Subcutaneous, and Intravenous), by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1804

Increasing prevalence of opioid overdosing in key countries such as the U.S. and Canada is expected to increase demand for naloxone and significantly drive global naloxone market’s growth over the forecast period. For instance, according to data published by Centers for Disease Control and Prevention (CDC) in 2018, in the U.S. over 630,000 people died from a drug overdose from 1999 to 2016, and in 2016 around 66% of the 63,600 drug overdose deaths involved an opioid. Furthermore, according to the same source in 2016 the number of deaths involving opioids overdose (which include prescription opioids, heroin, and fentanyl) was five times higher than that in 1999. Favorable reimbursement scenarios for naloxone products is also expected to boost the adoption of products and fuel the global naloxone market growth. For instance, NARCAN nasal spray, a naloxone intranasal spray provided by ADAPT Pharma Inc., has extensive public and private insurance coverage. ADAPT Pharma Inc., entered into an agreement with major Pharmacy Benefits Managers and insurance companies (including Medicaid) to ensure reasonable and affordable costs to the patient. According to ADAPT Pharma Inc.’s official website around 97% of the U.S. insured lives have access to NARCAN Nasal Spray Furthermore, global naloxone market growth is also expected to rise due to the collective initiatives by government and private organizations for increasing accessibility of naloxone products for emergency treatment opioid overdose.

In 2017, 47 states and Washington, DC in the U.S. expanded access to naloxone through legislation that permits prescriptions to people who are likely to encounter someone who might take drug overdose. In 2017, Ontario government provided naloxone kits to police and fire departments to manage emergency case of opioid overdose. Government offered naloxone kits to all 61 police services and 447 fire departments in the Ontario.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/naloxone-market-1804

Key Takeaways of the Naloxone Market:

The global naloxone market is expected to exhibit a CAGR of 11.4% over the forecast period (2018 – 2026), owing to frequent product launches, approval, and robust pipeline of novel biopharmaceutical products

North America held the dominant position in the global naloxone market and is expected to retain its dominance over the forecast period (2018 – 2026). This is due to the high rates of opioid overdose and due to presence of novel naloxone products such as Nacran nasal spray in the region. For instance, in February, Adapt Pharma Inc., launched Narcan nasal spray 4mg commercially in the U.S. market.

Europe is expected to witness significant growth over the forecast period due to increasing launches of new naloxone by key players in the region. For instance, in July 2017,, Indivior Inc., a subsidiary of Indivior Plc., received marketing authorization (MA) from the French Regulatory Agency ANSM for its new Nalscue naloxone hydrochloride nasal spray, indicated for emergency treatment of characterized or suspected opioid overdose, in France.

Furthermore, initiatives taken by manufacturers with regulatory bodies to increase access for naloxone products in case of emergency is also expected to have a positive impact on global naloxone market’s growth. For instance, in 2017, 47 states and Washington, DC in the U.S. have expanded access to naloxone through legislation that permits prescriptions to people who are likely to encounter someone who might take drug overdose.

Major players operating in the Naloxone Market include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1804

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Octreotide Market Size, Share, Outlook, and Opportunity Analysis, 2018– 2026

Octreotide Market Regional Analysis:-

North America is expected to hold a dominant position in the Octreotide Market due to the presence of key players and robust pipeline of products in the region. For instance, Octreotide capsules sponsored by Chaisma Inc.—a biopharmaceutical company based in the U.S.—completed phase 3 clinical trials in 2017 for treatment of acromegaly. LAR lanreotide sponsored by Memorial Sloan Kettering Cancer Center, based in New York City, is currently in phase 4 clinical trials since 2016. LAR lanreotide is indicated for treatment of neuroendocrine tumors. Novel drugs are expected to fuel growth of the Octreotide market in North America. For instance, in 2011 Mylan Pharmaceutical Ltd—a generic and pharmaceuticals specialty company based in the U.S.—launched the generic version of sandostatin i.e. Octreotide acetate injection USP (pre-filled syringes). Octreotide acetate injection USP is used to treat acromegaly. It is also used to inhibit and suppress severe diarrhea, which is associated with metastatic carcinoid tumors and vasoactive intestinal peptide tumors.

Europe is expected to show significant growth in the Octreotide market due to strategic mergers and acquisitions among key players. For instance, in 2017, Novartis AG—a Switzerland-based company—acquired Advanced Accelerator Applications, a France-based company—to increase the development of its therapeutics portfolio, which also includes development of Octreotide to cure oncology.

Octreotide is an octapeptide that resembles natural somatostatin pharmacologically. Octreotide acetate is widely used in treatment of some types of cancers, diarrhea, and tumors such as carcinoid, pancreatic islet cell tumors, and vasoactive intestinal peptide secreting tumors. Octreotide acetate is also used to treat acromegaly when the body produces excess of growth hormone, which causes enlarged feet, hands, face, and head.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1836

Octreotide Market Drivers:-

Major driver for growth of the Octreotide market is the robust pipeline of drugs in clinical trials. For instance, in 2016, Mario Negri Institute for pharmacological research completed phase 2 clinical trials of its Octreotide LAR in combination with tolvaptan drug for the treatment of autosomal dominant polycystic kidney disease. This disease has an effect on the glomerular rate and total kidney and cystic volume. Octreotide sponsored by Radbound University is in phase 3 clinical trials from 2016. This drug is under clinical trial for the treatment of angiodysplasia, vascular malformations, gastrointestinal hemorrhage, and anemia with Octreotide. Injection Octreotide, sponsored by PVS memorial hospital is in phase 4 clinical trials since 2016. This injection is indicated for treatment of pancreatic fistula and complications of pancreatoduodenectomy among patients with soft pancreas. Furthermore, CAM2029 is being tested, currently in phase 2, for acromegaly and neuroendocrine tumors by Camurus AB in collaboration with Novartis AG. Octreotide chloride is the active ingredient for this product.

Increasing number of launches pertaining to novel Octreotide acetate products by key players in the market is expected to drive market growth. For instance, in 2013, Sagent Pharmaceuticals, a U.S.-based biopharmaceutical company, launched its new drug Octreotide acetate, a samatostatin analog. This drug is used to reduce blood levels of IGF-I (soatomedinC) and growth hormone in acromegaly patients who do not adequately respond to or who cannot be treated by surgery, irradiation and bromocriptine mesylate

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/octreotide-market-1836

Increasing prevalence of disease such as acromegaly and cancer, is expected to increase the demand for Octreotide drugs, which in turn is expected to fuel market growth. According to a survey conducted by National Institute of Health in 2015, over 4 million people suffer from acromegaly in the U.S.

Lack of research and development for Octreotide acetate for the treatment of children, lactating and pregnant women is a major restraining factor in this market. Moreover, consumption of Octreotide acetate by pregnant women can cause problems in the growth of the fetus and hence, its adoption is limited among pregnant woman.

Octreotide Market Key Players:-

Key players operating in the Octreotide market include Samarth Pharma Pvt Ltd., Sun Pharmaceuticals Industries Ltd., Neiss Labs Pvt. Ltd., Novartis AG, and Unique Chemical Ltd. Major players in the market are adopting inorganic growth strategies such as mergers and acquisitions, to strengthen their foothold in the global market. For instance, in 2015, Sun Pharmaceutical Industries Ltd.—Mumbai-based company—acquired Ranbaxy laboratories Ltd.—India-based pharmaceutical company—to enhance its productivity and focus on development of therapeutic area, including development of new drugs of Octreotide acetate. Such strategic acquisition among key players in the market is expected to create a lucrative environment for growth of the Octreotide market in the near future.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1836

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Human Recombinant Insulin Market Opportunity Analysis-2026

The Global Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and is projected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026).

Key manufacturers are engaged in launching novel human insulin portfolio and gaining regulatory approval for their insulin product portfolio. For instance, in August 2014, Eli Lilly and Company launched Jardiance (empagliflozin) as a treatment option for Type 2 diabetes patients in the U.S. Jardiance is a sodium glucose co-transporter-2 (SGLT2) inhibitor with Type 2 diabetes patients. In March 2016, Biocon Limited collaborated with LaboratoriosPiSA S.A de CV (PiSA) to jointly develop and sell a generic recombinant human insulin in America. Biocon expects the product to launch by 2020 in the U.S. In February 2018, Novo Nordisk launched Fiaspa: a fast-acting mealtime insulin in the U.S. Fiaspa received U.S. FDA approval and indicated to improve glycemic control in adults with type 1 and type 2 diabetes. In December 2017, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Admelog. Admelog is a follow-on mealtime insulin, which helps people living with diabetes manage blood sugar levels at mealtime.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1797

Browse 35 Market Data Tables and 42 Figures spread through 205 Pages and in-depth TOC on "Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Forecast to 2026"

Efficient diabetes management and ease of use creates need for advancements in current solutions of both insulin and its delivery systems thereby, offering reduced patient discomfort. Glucose Responsive Insulin (GRI) or smart insulin is a novel technology for people with diabetes, which works by automatically reacting to blood sugar fluctuations in body and responds to changing blood glucose levels. The lower or higher blood sugar levels are lead to release of more or less insulin, respectively. Smart insulin decreases the number of regular blood tests required and also minimizes the number of daily dose of insulin injections. Researchers from the University of North Carolina have been working on a smart insulin patch. For instance, in 2015, researchers reported that, smart insulin patch can use a micro-needles system to automatically detect high blood glucose levels and administer insulin appropriately. Key players in the human recombinant insulin market are implementing inorganic growth strategies to develop and introduce smart insulin technology in the market. For instance, in February 2016, Eli Lilly and Company acquired Glycostasis, Inc., a startup company engaged in developing smart insulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smart insulin’ technology.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/human-recombinant-insulin-market-1797

Key takeaways of the Human Recombinant Insulin Market:

The global human recombinant insulin market is expected to expand at a CAGR of 7.2% during the forecast period (2018 – 2026), owing to increasing technological advancement in recombinant human insulin by various key players.

Long acting human insulin are projected to grow with higher pace during the forecasted period in the product type segment, owing to their higher efficiency and ability to offer consistent insulin delivery throughout the day, lasting 24 hours.

Other brands hold major market share in brand segment, due to the involvement of innovative and new human recombinant insulin portfolio with increased patent expiry period such as Toujeo, Tresiba, Basaglar, among others; in this segment, which further expected to capture higher market share, during the forecast period.

Retail pharmacies holds largest market share in distribution channel segment. As retail pharmacies offer direct access to full range of diabetes products, covering all prescription and over-the-counter products for patients with diabetes.

Some of the major players operating in global human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1797

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737